vs
DYCOM INDUSTRIES INC（DY）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
DYCOM INDUSTRIES INC的季度营收约是Revvity的1.9倍（$1.5B vs $772.1M），Revvity净利率更高（12.7% vs 7.3%，领先5.4%），DYCOM INDUSTRIES INC同比增速更快（14.1% vs 5.9%），DYCOM INDUSTRIES INC自由现金流更多（$164.8M vs $161.8M），过去两年DYCOM INDUSTRIES INC的营收复合增速更高（23.5% vs 9.0%）
本公司是美国基础设施服务供应商，服务覆盖电力、管道、工业、通信四大领域，具备各类网络基础设施的规划、设计、安装、项目管理、运维及抢修能力。成立以来坚持内生增长，同时已收购150多家电力承包行业企业，为众多大型电力领域客户提供专业服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
DY vs RVTY — 直观对比
营收规模更大
DY
是对方的1.9倍
$772.1M
营收增速更快
DY
高出8.3%
5.9%
净利率更高
RVTY
高出5.4%
7.3%
自由现金流更多
DY
多$3.0M
$161.8M
两年增速更快
DY
近两年复合增速
9.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $772.1M |
| 净利润 | $106.4M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 9.7% | 14.5% |
| 净利率 | 7.3% | 12.7% |
| 营收同比 | 14.1% | 5.9% |
| 净利润同比 | 52.4% | 3.9% |
| 每股收益（稀释后） | $3.63 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DYRVTY
| Q4 25 | $1.5B | $772.1M | ||
| Q3 25 | $1.4B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.1B | $664.8M | ||
| Q4 24 | $1.3B | $729.4M | ||
| Q3 24 | $1.2B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M | ||
| Q1 24 | $952.5M | $649.9M |
净利润DYRVTY
| Q4 25 | $106.4M | $98.4M | ||
| Q3 25 | $97.5M | $46.7M | ||
| Q2 25 | $61.0M | $53.9M | ||
| Q1 25 | $32.7M | $42.2M | ||
| Q4 24 | $69.8M | $94.6M | ||
| Q3 24 | $68.4M | $94.4M | ||
| Q2 24 | $62.6M | $55.4M | ||
| Q1 24 | $23.4M | $26.0M |
毛利率DYRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率DYRVTY
| Q4 25 | 9.7% | 14.5% | ||
| Q3 25 | 9.5% | 11.7% | ||
| Q2 25 | 6.2% | 12.6% | ||
| Q1 25 | 4.1% | 10.9% | ||
| Q4 24 | 7.2% | 16.3% | ||
| Q3 24 | 7.9% | 14.3% | ||
| Q2 24 | 6.8% | 12.4% | ||
| Q1 24 | 3.3% | 6.8% |
净利率DYRVTY
| Q4 25 | 7.3% | 12.7% | ||
| Q3 25 | 7.1% | 6.7% | ||
| Q2 25 | 4.9% | 7.5% | ||
| Q1 25 | 3.0% | 6.4% | ||
| Q4 24 | 5.5% | 13.0% | ||
| Q3 24 | 5.7% | 13.8% | ||
| Q2 24 | 5.5% | 8.0% | ||
| Q1 24 | 2.5% | 4.0% |
每股收益（稀释后）DYRVTY
| Q4 25 | $3.63 | $0.86 | ||
| Q3 25 | $3.33 | $0.40 | ||
| Q2 25 | $2.09 | $0.46 | ||
| Q1 25 | $1.11 | $0.35 | ||
| Q4 24 | $2.37 | $0.77 | ||
| Q3 24 | $2.32 | $0.77 | ||
| Q2 24 | $2.12 | $0.45 | ||
| Q1 24 | $0.79 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $110.1M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.5B | $7.3B |
| 总资产 | $3.3B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DYRVTY
| Q4 25 | $110.1M | $919.9M | ||
| Q3 25 | $28.5M | $931.4M | ||
| Q2 25 | $16.1M | $991.8M | ||
| Q1 25 | $92.7M | $1.1B | ||
| Q4 24 | $15.3M | $1.2B | ||
| Q3 24 | $19.6M | $1.2B | ||
| Q2 24 | $26.1M | $2.0B | ||
| Q1 24 | $101.1M | $1.7B |
股东权益DYRVTY
| Q4 25 | $1.5B | $7.3B | ||
| Q3 25 | $1.4B | $7.4B | ||
| Q2 25 | $1.3B | $7.6B | ||
| Q1 25 | $1.2B | $7.6B | ||
| Q4 24 | $1.2B | $7.7B | ||
| Q3 24 | $1.2B | $7.9B | ||
| Q2 24 | $1.1B | $7.9B | ||
| Q1 24 | $1.1B | $7.8B |
总资产DYRVTY
| Q4 25 | $3.3B | $12.2B | ||
| Q3 25 | $3.2B | $12.1B | ||
| Q2 25 | $3.1B | $12.4B | ||
| Q1 25 | $2.9B | $12.4B | ||
| Q4 24 | $3.1B | $12.4B | ||
| Q3 24 | $2.8B | $12.8B | ||
| Q2 24 | $2.6B | $13.4B | ||
| Q1 24 | $2.5B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $220.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $164.8M | $161.8M |
| 自由现金流率自由现金流/营收 | 11.4% | 21.0% |
| 资本支出强度资本支出/营收 | 3.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.07× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $296.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流DYRVTY
| Q4 25 | $220.0M | $182.0M | ||
| Q3 25 | $57.4M | $138.5M | ||
| Q2 25 | $-54.0M | $134.3M | ||
| Q1 25 | $328.2M | $128.2M | ||
| Q4 24 | $65.8M | $174.2M | ||
| Q3 24 | $-7.5M | $147.9M | ||
| Q2 24 | $-37.4M | $158.6M | ||
| Q1 24 | $325.1M | $147.6M |
自由现金流DYRVTY
| Q4 25 | $164.8M | $161.8M | ||
| Q3 25 | $5.8M | $120.0M | ||
| Q2 25 | $-133.5M | $115.5M | ||
| Q1 25 | $259.7M | $112.2M | ||
| Q4 24 | $-8.8M | $149.8M | ||
| Q3 24 | $-72.9M | $125.6M | ||
| Q2 24 | $-79.4M | $136.6M | ||
| Q1 24 | $267.7M | $129.7M |
自由现金流率DYRVTY
| Q4 25 | 11.4% | 21.0% | ||
| Q3 25 | 0.4% | 17.2% | ||
| Q2 25 | -10.6% | 16.0% | ||
| Q1 25 | 23.9% | 16.9% | ||
| Q4 24 | -0.7% | 20.5% | ||
| Q3 24 | -6.1% | 18.4% | ||
| Q2 24 | -6.9% | 19.7% | ||
| Q1 24 | 28.1% | 20.0% |
资本支出强度DYRVTY
| Q4 25 | 3.8% | 2.6% | ||
| Q3 25 | 3.8% | 2.6% | ||
| Q2 25 | 6.3% | 2.6% | ||
| Q1 25 | 6.3% | 2.4% | ||
| Q4 24 | 5.9% | 3.4% | ||
| Q3 24 | 5.4% | 3.3% | ||
| Q2 24 | 3.7% | 3.2% | ||
| Q1 24 | 6.0% | 2.7% |
现金转化率DYRVTY
| Q4 25 | 2.07× | 1.85× | ||
| Q3 25 | 0.59× | 2.97× | ||
| Q2 25 | -0.88× | 2.49× | ||
| Q1 25 | 10.05× | 3.03× | ||
| Q4 24 | 0.94× | 1.84× | ||
| Q3 24 | -0.11× | 1.57× | ||
| Q2 24 | -0.60× | 2.87× | ||
| Q1 24 | 13.88× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DY
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
